ReShape Lifesciences raises $1.2M via warrant exercise with existing accredited investor

Vyome Holdings, Inc

Gross proceeds ~$1.2M from exercise of 5,382,500 warrants at reduced price of $0.23/share.
New warrants issued for 10,765,000 shares (200% coverage) at $0.23, exercisable in 6 months for 5.5 years.
Exercise price of existing warrants reduced from $0.2503 to $0.23; also reduces price on 6,960,351 unexercised warrants.
Beneficial ownership limits: 9.99% for existing, 4.99% for new warrants.
Proceeds earmarked for commercial growth, working capital, and general corporate purposes. Maxim Group acted as agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vyome Holdings, Inc entered into warrant exercise agreement with an existing accredited investor valued at approximately $1.2 million (effective 2023-11-21).

Agreement: equity purchase
Counterparty: an existing accredited investor
Value: approximately $1.2 million
Effective: 2023-11-21

Exact text from the filing

On November 21, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants

View on SEC.gov

Browse all material agreements →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001558370-23-019380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.